My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.73 -0.54 (-2.14%)
Streaming Delayed Price Updated: 12:52 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures
From Pacira BioSciences
Via GlobeNewswire
Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
From Pacira BioSciences
Via GlobeNewswire
Analyst Expectations for Pacira BioSciences's Future
 
Via Benzinga
Earnings Preview For Pacira BioSciences
 
Via Benzinga
Where Pacira BioSciences Stands With Analysts
 
Via Benzinga
Pacira BioSciences's Return On Capital Employed Insights
 
Via Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions
Multi-year agreement will make Pacira’s medical device ioveraº the Official Non-Opioid Pain Management Partner of the LPGA 
From Pacira BioSciences
Via GlobeNewswire
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
 
Via Benzinga
Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug
 
Via Benzinga
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
From Pacira BioSciences
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 12 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 16 companies set new 52-week lows. 
Via Benzinga
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 49 companies hit new 52-week lows. 
Via Benzinga
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
EXPAREL sales were 99 percent and unit volumes were 104 percent of November 2021 
From Pacira BioSciences
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences: Q3 Earnings Insights
Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pacira BioSciences Reports Third Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September -- 
From Pacira BioSciences
Via GlobeNewswire
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.